Efficacy and safety of moxibustion for fatigue in peritoneal dialysis population: a randomized controlled pilot trial

INTERVENTION: Therapy group:moxibustion;Waiting‐list group:None; CONDITION: Peritoneal Dialysis‐Related Fatigue PRIMARY OUTCOME: Piper Fatigue Score;Proportion of subjects achieving target treatment regimen; SECONDARY OUTCOME: Peritoneal dialysis‐related laboratory indicators(Blood creatinine, blood uremic nitrogen, serum albumin, hemoglobin, blood calcium, blood phosphorus, parathyroid hormone, urea clearance inde X(Kt/V), total creatinine clearance);Quality of Life Questionnaire (QLQ‐C30);Pittsburgh quality index;Hospital Anxiety and Depression Scale;International Physical Activity Questionnaire – Short Form; INCLUSION CRITERIA: (1) Adults aged 18 years or older. (2) Maintenance peritoneal dialysis treatment for 4 months or longer before participating in the trial. (3) Fatigue symptom persisting for at least 4 weeks or longer, with a Piper Fatigue Inventory score of 4 or higher. (4) Able to communicate verbally, without communication or cognitive impairment. (5) Willing to participate in the trial and provide written consent.